Unibest
← Back to patent-cliff list

CAS 1283129-18-9

(2S,3S,4R,5R,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)

Codes: CANA-019

Application context (from source-drug indications)

End-stage renal diseaseCanagliflozin/Metformin HydrochlorideCardiac and vascular disordersCanagliflozin/Metformin HydrochlorideAbdominal aortic aneurysmCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin/Metformin HydrochlorideType 2 diabetesCanagliflozin HemihydrateDiabetic nephropathyCanagliflozin HemihydrateCoronary artery lesionCanagliflozin HemihydrateDiabetesCanagliflozin HemihydrateHeart failureCanagliflozin HemihydrateEnd-stage renal diseaseCanagliflozin Hemihydrate

Source drugs (routes using this intermediate)

DrugTierExpiry
Canagliflozin/Metformin HydrochlorideTier B — Position early2029
Canagliflozin HemihydrateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.